These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16684124)

  • 1. In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
    Agis H; Jaeger E; Doninger B; Sillaber C; Marosi C; Drach J; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2006 Jun; 36(6):402-8. PubMed ID: 16684124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.
    Balabanov S; Appel S; Kanz L; Brossart P; Brümmendorf TH
    Ann N Y Acad Sci; 2005 Jun; 1044():168-77. PubMed ID: 15958710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of imatinib on normal hematopoiesis and immune activation.
    Appel S; Balabanov S; Brümmendorf TH; Brossart P
    Stem Cells; 2005 Sep; 23(8):1082-8. PubMed ID: 16140870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
    Michor F
    Trends Pharmacol Sci; 2007 May; 28(5):197-9. PubMed ID: 17412430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
    Amiel A; Yukla M; Gaber E; Leopold L; Josef G; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 2006 Jul; 168(2):120-3. PubMed ID: 16843101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
    Holtz M; Forman SJ; Bhatia R
    Cancer Res; 2007 Feb; 67(3):1113-20. PubMed ID: 17283145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
    Perseghin P; Gambacorti-Passerini C; Tornaghi L; Dassi M; Pioltelli P; Parma M; Colnaghi F; Giudici G; Elli E; Fumagalli M; Ponchio L; Biondi A; Pogliani EM
    Transfusion; 2005 Jul; 45(7):1214-20. PubMed ID: 15987369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
    Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
    Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
    Giralt SA; Arora M; Goldman JM; Lee SJ; Maziarz RT; McCarthy PL; Sobocinski KA; Horowitz MM;
    Br J Haematol; 2007 Jun; 137(5):461-7. PubMed ID: 17459051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
    J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Angstreich GR; Matsui W; Huff CA; Vala MS; Barber J; Hawkins AL; Griffin CA; Smith BD; Jones RJ
    Br J Haematol; 2005 Aug; 130(3):373-81. PubMed ID: 16042686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
    Aswald JM; Lipton JH; Aswald S; Messner HA
    Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
    Agarwal MB
    J Assoc Physicians India; 2007 Feb; 55():99-100. PubMed ID: 17571737
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
    Mattiuzzi GN; Cortes JE; Talpaz M; Reuben J; Rios MB; Shan J; Kontoyiannis D; Giles FJ; Raad I; Verstovsek S; Ferrajoli A; Kantarjian HM
    Clin Cancer Res; 2003 Mar; 9(3):976-80. PubMed ID: 12631595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.